Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33305) 33305
Newsletter (3668) 3668
Publication (2520) 2520
Newspaper Article (476) 476
Magazine Article (231) 231
Book Review (178) 178
Book Chapter (119) 119
Government Document (84) 84
Conference Proceeding (63) 63
Dissertation (52) 52
Trade Publication Article (50) 50
Web Resource (18) 18
Book / eBook (17) 17
Reference (9) 9
Transcript (7) 7
Paper (5) 5
Data Set (3) 3
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27103) 27103
male (25457) 25457
prostate cancer (18434) 18434
prostate-specific antigen (17721) 17721
prostate-specific antigen - blood (16594) 16594
aged (13919) 13919
middle aged (13648) 13648
index medicus (11635) 11635
cancer (10582) 10582
prostatic neoplasms - pathology (10052) 10052
urology & nephrology (9157) 9157
prostatic neoplasms - blood (8444) 8444
prostatic neoplasms - diagnosis (7453) 7453
oncology (7220) 7220
aged, 80 and over (5396) 5396
research (5286) 5286
prostatic neoplasms - surgery (4573) 4573
diagnosis (4547) 4547
prostate (4544) 4544
radical prostatectomy (4380) 4380
adult (4254) 4254
men (4186) 4186
prostatectomy (4080) 4080
biopsy (3973) 3973
prognosis (3926) 3926
neoplasm staging (3672) 3672
care and treatment (3566) 3566
carcinoma (3432) 3432
antigen (3358) 3358
treatment outcome (3204) 3204
retrospective studies (3147) 3147
prostate - pathology (3130) 3130
biomarkers, tumor - blood (3043) 3043
risk factors (3038) 3038
prostatic neoplasms (2872) 2872
urology (2872) 2872
prostatic neoplasms - drug therapy (2794) 2794
prostatic neoplasms - therapy (2739) 2739
antigens (2683) 2683
analysis (2674) 2674
oncology, experimental (2671) 2671
prostatic neoplasms - mortality (2621) 2621
sensitivity and specificity (2613) 2613
prostatic neoplasms - radiotherapy (2609) 2609
follow-up studies (2530) 2530
prostate-specific antigen - analysis (2512) 2512
predictive value of tests (2445) 2445
psa (2429) 2429
radiotherapy (2319) 2319
health aspects (2269) 2269
risk (2221) 2221
prostate-specific antigen - metabolism (2106) 2106
time factors (2059) 2059
adenocarcinoma (1962) 1962
prostate specific antigen (1957) 1957
prostatic neoplasms - metabolism (1919) 1919
prospective studies (1898) 1898
mortality (1897) 1897
disease-free survival (1823) 1823
surgery (1808) 1808
disease progression (1760) 1760
animals (1753) 1753
female (1747) 1747
metastasis (1681) 1681
radiology, nuclear medicine & medical imaging (1671) 1671
survival (1662) 1662
prostatic neoplasms - epidemiology (1616) 1616
serum (1604) 1604
neoplasm grading (1585) 1585
article (1561) 1561
expression (1530) 1530
medicine, general & internal (1511) 1511
therapy (1503) 1503
progression (1494) 1494
prostatic neoplasms - genetics (1486) 1486
abridged index medicus (1450) 1450
prostatectomy - methods (1395) 1395
adenocarcinoma - pathology (1367) 1367
risk assessment (1332) 1332
prostatic neoplasms - diagnostic imaging (1331) 1331
tumors (1326) 1326
androgen antagonists - therapeutic use (1319) 1319
prostatic neoplasms - immunology (1310) 1310
reports (1286) 1286
radiation-therapy (1269) 1269
immunohistochemistry (1259) 1259
multivariate analysis (1257) 1257
digital rectal examination (1234) 1234
mass screening (1221) 1221
usage (1217) 1217
recurrence (1180) 1180
prostatic neoplasms - prevention & control (1156) 1156
age factors (1135) 1135
medicine & public health (1120) 1120
endocrinology & metabolism (1100) 1100
survival rate (1087) 1087
patients (1058) 1058
survival analysis (1057) 1057
prostate-specific antigen - genetics (1041) 1041
adenocarcinoma - blood (1033) 1033
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (34977) 34977
German (594) 594
Japanese (559) 559
French (512) 512
Spanish (433) 433
Chinese (276) 276
Russian (188) 188
Italian (100) 100
Turkish (43) 43
Dutch (34) 34
Korean (31) 31
Hungarian (29) 29
Norwegian (29) 29
Swedish (28) 28
Portuguese (25) 25
Polish (21) 21
Danish (18) 18
Czech (15) 15
Serbian (12) 12
Hebrew (10) 10
Croatian (9) 9
Slovak (8) 8
Finnish (7) 7
Persian (6) 6
Lithuanian (5) 5
Romanian (5) 5
Bulgarian (4) 4
Greek (2) 2
Ukrainian (2) 2
Arabic (1) 1
Estonian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml)
by Çaliskan, Selahattin
Journal of Cancer Research and Therapeutics, ISSN 0973-1482, 04/2017, Volume 13, Issue 2, pp. 279 - 283
Aim of Study: Serum prostate-specific antigen (PSA) is a useful tumor biomarker for prostate cancer (PCa) diagnosis. In this study, I aimed to compare the... 
specificity | free/total prostate-specific antigen | prostate cancer | Diagnosis | sensitivity | IMPROVE | COMPLEX | BIOPSY | MARKERS | SERUM | PERCENTAGE | ONCOLOGY | VALUES | PSA | Humans | Middle Aged | Sensitivity and Specificity | Male | Aged | Prostatic Neoplasms - diagnosis | Prostate-Specific Antigen - blood | Research | Prostate-specific antigen | Prostate cancer | Antigens | Ultrasonic imaging | Biopsy | Medical screening | Medical diagnosis | Patients | Urology | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Prostate-specific Antigen Mass Density—A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution
by Kryvenko, Oleksandr N and Diaz, Mireya and Matoso, Andres and Kates, Max and Cohen, Jason and Swanson, Gregory P and Epstein, Jonathan I
Urology, ISSN 0090-4295, 2016, Volume 90, pp. 141 - 147
Objective To test prostate-specific antigen mass density (PSAMD) as a predictor of total tumor volume (TTV) at radical prostatectomy (RP). Methods We conducted... 
Urology | SPECIMENS | PSA MASS | ACTIVE SURVEILLANCE | BIOPSY | INTERNATIONAL SOCIETY | UROLOGY & NEPHROLOGY | RISK | GRADE | RADICAL PROSTATECTOMY | UROLOGICAL PATHOLOGY | AMERICAN MEN | Body Mass Index | Predictive Value of Tests | Prostatic Neoplasms - pathology | Overweight - complications | Prostatic Neoplasms - surgery | Obesity - complications | Humans | Middle Aged | Male | Tumor Burden | Obesity - blood | Plasma Volume | Prostate-Specific Antigen - blood | Overweight - blood | Prostatic Neoplasms - blood | Adult | Prostatectomy | Aged | Prostatic Neoplasms - complications | Antigens | Obesity | Specific gravity | Prostate cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Prostate-Specific Antigen–Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force
by Fenton, Joshua J and Weyrich, Meghan S and Durbin, Shauna and Liu, Yu and Bang, Heejung and Melnikow, Joy
JAMA, ISSN 0098-7484, 05/2018, Volume 319, Issue 18, pp. 1914 - 1931
IMPORTANCE: Prostate cancer is the second leading cause of cancer death among US men. OBJECTIVE: To systematically review evidence on prostate-specific antigen... 
MEDICINE, GENERAL & INTERNAL | EXTERNAL-BEAM RADIOTHERAPY | RANDOMIZED PROSTATE | 30-DAY MORTALITY | ACTIVE SURVEILLANCE | RISK CALCULATOR 2.0 | FOLLOW-UP | RADICAL PROSTATECTOMY | QUALITY-OF-LIFE | RADIATION-THERAPY | ROTTERDAM SECTION | Treatment outcome | Usage | Diagnosis | Prostate-specific antigen | Prostate cancer | Analysis | Pollution control | Radiation | Clinical trials | Risk factors | Metastases | Randomization | Mathematical analysis | Antigens | Medical research | Calculators | Complications | Medical treatment | Mortality | Health risks | Risk reduction | Erectile dysfunction | Radiation therapy | Medical screening | Disease control | Contamination | Screening | Surveillance | Biopsy | Men | Risk management | Prostate | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (≥100)
by Roobol, Monique J and Schröder, Fritz H and van Leenders, Geert L.J.H and Hessels, Daphne and van den Bergh, Roderick C.N and Wolters, Tineke and van Leeuwen, Pim J
European Urology, ISSN 0302-2838, 2010, Volume 58, Issue 6, pp. 893 - 899
Abstract Background Prostate cancer antigen 3 (PCA3) is considered to be prostate cancer (PCa) specific and highly overexpressed in cancer. Therefore a high... 
Urology | PCA3 | Performance characteristics | Diagnosis | Prostate cancer | PSA | MOLECULAR URINE TEST | DD3 | REPEAT BIOPSY | ASSAY | VALIDATION | UROLOGY & NEPHROLOGY | Predictive Value of Tests | Prostatic Neoplasms - pathology | Reproducibility of Results | Prognosis | Humans | Middle Aged | Male | Prostatic Neoplasms - diagnosis | Mass Screening - methods | Antigens, Neoplasm - urine | Freezing | Prostate-Specific Antigen - blood | Prostatic Neoplasms - immunology | Specimen Handling | Netherlands | Biopsy | Sensitivity and Specificity | Aged | Antigens | Care and treatment | Cancer patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
by Catalona, William J and Partin, Alan W and Sanda, Martin G and Wei, John T and Klee, George G and Bangma, Chris H and Slawin, Kevin M and Marks, Leonard S and Loeb, Stacy and Broyles, Dennis L and Shin, Sanghyuk S and Cruz, Amabelle B and Chan, Daniel W and Sokoll, Lori J and Roberts, William L and van Schaik, Ron H.N and Mizrahi, Isaac A
Journal of Urology, The, ISSN 0022-5347, 2011, Volume 185, Issue 5, pp. 1650 - 1655
Purpose Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer,... 
Urology | prostate specific antigen | diagnosis | prostate | mass screening | prostatic neoplasms | MORTALITY | CONFIDENCE-INTERVALS | CLINICAL-TRIAL | SERUM | LEVEL | DETECTION RESEARCH NETWORK | MEN | UROLOGY & NEPHROLOGY | PSA | Predictive Value of Tests | Prospective Studies | Age Factors | Double-Blind Method | Area Under Curve | Humans | Middle Aged | Male | Prostatic Neoplasms - diagnosis | Chi-Square Distribution | Case-Control Studies | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Regression Analysis | Mass Screening | Biopsy | Sensitivity and Specificity | Prostatic Neoplasms - blood | Aged | Medical colleges | Prostate-specific antigen | Diagnosis | Medical screening | Prostate cancer | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Percent decrease of serum prostate-specific antigen after dutasteride administration is equivalent in men with clinical benign prostatic hyperplasia having baseline prostate-specific antigen >10 ng/mL and those having baseline prostate-specific antigen 2.5–10 ng/mL
by Takeshita, Hideki and Kawakami, Satoru and Yano, Akihiro and Okada, Yohei and Morozumi, Makoto and Yamada, Takumi
International Journal of Urology, ISSN 0919-8172, 03/2017, Volume 24, Issue 3, pp. 238 - 239
UROLOGY & NEPHROLOGY | Antigens | Statistics | Hyperplasia | Prostate-specific antigen | Prostate | Benign
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
by Thompson, Ian M and Pauler, Donna K and Goodman, Phyllis J and Tangen, Catherine M and Lucia, M. Scott and Parnes, Howard L and Minasian, Lori M and Ford, Leslie G and Lippman, Scott M and Crawford, E. David and Crowley, John J and Coltman, Charles A
The New England Journal of Medicine, ISSN 0028-4793, 05/2004, Volume 350, Issue 22, pp. 2239 - 2246
Almost 3000 men who received a placebo in the Prostate Cancer Prevention Trial and who never had a prostate-specific antigen (PSA) level of more than 4.0 ng... 
MORTALITY | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | ULTRASOUND | BIOPSY | MARKERS | ACID-PHOSPHATASE | SERUM | CARCINOMA | PREVENTION TRIAL | Prostatic Neoplasms - pathology | Prevalence | Humans | Middle Aged | Male | Risk | Prostate-Specific Antigen - blood | Prostatic Neoplasms - epidemiology | Prostate - pathology | Biopsy | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Prostatic Neoplasms - blood | Aged | Finasteride - therapeutic use | Prostatic Neoplasms - prevention & control | Clinical trials | Medical diagnosis | Prostate cancer | Men
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms
by Gulati, Roman and Gore, John L and Etzioni, Ruth
Annals of Internal Medicine, ISSN 0003-4819, 02/2013, Volume 158, Issue 3, pp. 145 - 153
Background: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh... 
MORTALITY | TRIAL | POPULATION | MEDICINE, GENERAL & INTERNAL | RANDOMIZED PROSTATE | SERVICES TASK-FORCE | VIEWPOINT | FOLLOW-UP | QUALITY-OF-LIFE | BIOPSIES | Prostatic Neoplasms - pathology | Early Detection of Cancer - methods | Risk Assessment | Humans | Middle Aged | Male | Prostatic Neoplasms - diagnosis | False Positive Reactions | Mass Screening - methods | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Incidence | Prostatic Neoplasms - epidemiology | Comparative Effectiveness Research | Neoplasm Grading | Time Factors | Biopsy | Computer Simulation | Aged, 80 and over | Aged | Safety and security measures | Diagnosis | Research | Comparative analysis | Prostate cancer | Methods | Immune system | Testing | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge®)
by Harzstark, Andrea L and Small, Eric J
Expert Opinion on Biological Therapy, ISSN 1471-2598, 08/2007, Volume 7, Issue 8, pp. 1275 - 1280
Dendritic cells are deficient both in number and function in patients with cancer. Loaded dendritic cell therapies aim to overcome this deficiency by... 
prostatic acid phosphatase | prostate cancer | Provenge | dendritic cell | immunotherapy | Dendritic cell | Prostatic acid phosphatase | Prostate cancer | Immunotherapy | MEDICINE, RESEARCH & EXPERIMENTAL | MITOXANTRONE | DENDRITIC CELLS | DOCETAXEL | TRIAL | PREDNISONE | THERAPY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ACID-PHOSPHATASE | PROGRESSION | Cancer Vaccines - immunology | Cancer Vaccines - therapeutic use | Animals | Humans | Tissue Extracts - immunology | Male | Prostate-Specific Antigen - immunology | Tissue Extracts - therapeutic use | Antigen-Presenting Cells - immunology | Prostatic Neoplasms - immunology | Prostatic Neoplasms - therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
by Hayes, Julia H and Barry, Michael J
JAMA, ISSN 0098-7484, 03/2014, Volume 311, Issue 11, pp. 1143 - 1149
IMPORTANCE Prostate cancer screening with the prostate-specific antigen (PSA) test remains controversial. OBJECTIVE To review evidence from randomized trials... 
MORTALITY | STATEMENT | MEDICINE, GENERAL & INTERNAL | MEN | SERVICES TASK-FORCE | FOLLOW-UP | RISK | RADICAL PROSTATECTOMY | RANDOMIZED CONTROLLED-TRIAL | OUTCOMES | RECOMMENDATION | Models, Theoretical | Early Detection of Cancer | Humans | Middle Aged | Male | Reference Values | Prostatic Neoplasms - diagnosis | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Randomized Controlled Trials as Topic | Mass Screening | Aged, 80 and over | Prostatic Neoplasms - blood | Aged | Usage | Diagnosis | Research | Prostate cancer | Immune system | Testing | Clinical trials | Mens health | Medical screening | Mortality | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer
by Schmuck, Sebastian and Nordlohne, Stefan and von Klot, Christoph-A and Henkenberens, Christoph and Sohns, Jan M and Christiansen, Hans and Wester, Hans-Jürgen and Ross, Tobias L and Bengel, Frank M and Derlin, Thorsten
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 06/2017, Volume 44, Issue 6, pp. 960 - 968
Purpose The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate... 
Detection rate | Dual-phase imaging | Delayed imaging | PSMA | Prostate cancer | PET/CT | RADIATION-DOSIMETRY | TOMOGRAPHY | MEMBRANE ANTIGEN | BIODISTRIBUTION | GA-68-PSMA LIGAND PET/CT | FAILURE | LESIONS | HBED-CC | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Prostatic Neoplasms - metabolism | Prostatic Neoplasms - pathology | Recurrence | Follow-Up Studies | Oligopeptides | Humans | Middle Aged | Male | Prostatic Neoplasms - therapy | Reference Standards | Image Processing, Computer-Assisted | Time Factors | Aged, 80 and over | Prostatic Neoplasms - diagnostic imaging | Coordination Complexes | Aged | Prostate-Specific Antigen - metabolism | Retrospective Studies | Positron Emission Tomography Computed Tomography - methods | Positron Emission Tomography Computed Tomography - standards | Comparative studies | Antigens | Ligands | Biochemistry | Medical imaging
Journal Article
Details down arrow
12. Full Text The Clinical Course of Patients With Prostate-Specific Antigen ≥100 ng/ml: Insight Into a Potential Population for Targeted Prostate-Specific Antigen Screening
by Leung, Andrew K and Hugar, Lee and Patil, Dattatraya and Wong, Lisa and Carthon, Bradley and Carney, K. Jeff and Birdsong, George and Moses, Kelvin A and Master, Viraj A
Urology, ISSN 0090-4295, 07/2018, Volume 117, pp. 101 - 107
To characterize men presenting to a tertiary care safety-net hospital with prostate-specific antigen (PSA) values ≥100 ng/mL and to identify a potential... 
UNITED-STATES | MORTALITY | MEN | UROLOGY & NEPHROLOGY | CANCER | BURDEN | CARE | Safety-net Providers - statistics & numerical data | United States | Humans | Medicare - statistics & numerical data | Middle Aged | Male | Medicaid - statistics & numerical data | Prostatic Neoplasms - diagnosis | Prisoners - statistics & numerical data | Prostatic Neoplasms - therapy | Neoplasm Metastasis | Neoplasm Grading | Aged, 80 and over | Prostatic Neoplasms - blood | Adult | Retrospective Studies | Early Detection of Cancer - statistics & numerical data | Homeless Persons - statistics & numerical data | Prostatic Neoplasms - pathology | Survival Rate | Marital Status | Prostate-Specific Antigen - blood | African Americans - statistics & numerical data | Residence Characteristics - statistics & numerical data | Aged | Georgia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A comparative performance analysis of total prostate‐specific antigen, percentage free prostate‐specific antigen, prostate‐specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy
by Auprich, Marco and Augustin, Herbert and Budäus, Lars and Kluth, Luis and Mannweiler, Sebastian and Shariat, Shahrokh F and Fisch, Margit and Graefen, Markus and Pummer, Karl and Chun, Felix K.‐H
BJU International, ISSN 1464-4096, 06/2012, Volume 109, Issue 11, pp. 1627 - 1635
Study Type Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Risk factor assessment in the repeat... 
prostate cancer | urinary prostate cancer gene 3 | percentage free PSA | PSA velocity | total PSA | repeat prostate biopsy | DIAGNOSIS | ASSAY | SATURATION BIOPSY | PCA3 SCORE | PREVIOUS NEGATIVE BIOPSIES | VALIDATION | FOLLOW-UP | MEN | SEXTANT BIOPSIES | UROLOGY & NEPHROLOGY | NEEDLE-BIOPSY | Predictive Value of Tests | Prostatic Neoplasms - metabolism | Prostatic Neoplasms - pathology | Digital Rectal Examination | Humans | Middle Aged | RNA, Messenger - genetics | Risk Factors | Male | RNA, Messenger - metabolism | Antigens, Neoplasm - urine | Prostate-Specific Antigen - blood | ROC Curve | Aged | Biopsy, Needle | Cohort Studies | Biopsy | Prostate cancer | Accuracy | Neoplasia | Risk factors | Rectum | prostate-specific antigen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
by Perera, Marlon and Papa, Nathan and Roberts, Matthew and Williams, Michael and Udovicich, Cristian and Vela, Ian and Christidis, Daniel and Bolton, Damien and Hofman, Michael S and Lawrentschuk, Nathan and Murphy, Declan G
European Urology, ISSN 0302-2838, 2019
Context: Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is becoming increasingly more important in guiding local and... 
Sensitivity | Prostate-specific antigen | Imaging | Prostate-specific membrane antigen | Biochemical recurrence | Positron emission tomography | Prostate cancer | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml^-1
by Rui Chen Li-Qun Zhou Xiao-Bing Cai Li-Ping Xie Yi-Ran Huang Da-Lin He Xu Gao Chuan-Liang Xu Qiang Ding Qiang wei Chang-Jun Yin Shan-Cheng Ren Fu-Bo Wang Ye Tian Zhong-Quan Sun Qiang Fu Lu-Lin Ma Jun-Hua Zheng Zhang-Qun Ye Ding-Wei Ye Dan-Feng Xu Jian-Quan Hou Ke-Xin Xu Jian-Lin Yuan Xin Gao Chun-Xiao Liu Tie-Jun Pan Ying-Hao Sun
亚洲男性学杂志：英文版, ISSN 1008-682X, 2015, Volume 17, Issue 6, pp. 1017 - 1021
Percent free prostatic-specific antigen （%fPSA） has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng... 
前列腺癌 | 特异性抗原 | 预测 | 诊断准确性 | 活检 | 中国 | 游离 | 男性 | Chinese population | Prostate carcinoma tumor antigen | Diagnosis | Prostate-specific antigen | Prostate cancer | Percent free prostate-specific antigen | Measurement | Usage | Prognosis | Biopsy | Physiological aspects | Research | Prostate | Studies | Antigens | Mens health | Accuracy | Population | FDA approval | Multivariate analysis | Urology | Logistics | prostate cancer | diagnosis | percent free prostate-specific antigen | prostate carcinoma tumor antigen | Original | prostate-specific antigen | Chinese population; diagnosis; percent free prostate-specific antigen; prostate cancer; prostate carcinoma tumor antigen; prostate-specific antigen
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights